Cellectar Biosciences Inc’s filing revealed that its Chief Operating Officer Longcor Jarrod acquired Company’s shares for reported $8400.0 on Jan 10 ’25. In the deal valued at $0.28 per share,30,000 shares were bought. As a result of this transaction, Longcor Jarrod now holds 83,141 shares worth roughly $28267.940000000002.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. ROTH Capital started covering the stock on September 13, 2019. It rated CLRB as “a Buy”.
Price Performance Review of CLRB
On Monday, Cellectar Biosciences Inc [NASDAQ:CLRB] saw its stock jump 6.72% to $0.34. Over the last five days, the stock has gained 6.89%. Cellectar Biosciences Inc shares have risen nearly 12.64% since the year began. Nevertheless, the stocks have fallen -90.49% over the past one year. While a 52-week high of $4.17 was reached on 01/06/25, a 52-week low of $0.22 was recorded on 01/15/25. SMA at 50 days reached $0.2890, while 200 days put it at $1.5956.
Levels Of Support And Resistance For CLRB Stock
The 24-hour chart illustrates a support level at 0.3174, which if violated will result in even more drops to 0.2979. On the upside, there is a resistance level at 0.3489. A further resistance level may holdings at 0.3609. The Relative Strength Index (RSI) on the 14-day chart is 57.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0137, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 6.57%. Stochastics %K at 68.89% indicates the stock is a holding.
How much short interest is there in Cellectar Biosciences Inc?
A steep rise in short interest was recorded in Cellectar Biosciences Inc stocks on 2025-02-28, dropping by -0.39 million shares to a total of 1.97 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 2.36 million shares. There was a decline of -19.72%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 21, 2016 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $2.70 price target.
